However, Xu et al. reported that all-LAT can prolong both PFS and OS compared with partial-LAT in patients with synchronous oligometastatic stage IV EGFR-mutant NSCLC [38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.